Shots:
- The company has received manufacturing and marketing approval in Japan for tocilizumab BS MA, a biosimilar version of Actemra (tocilizumab)
- Tocilizumab BS MA, a biosimilar jointly developed by Mochida Pharmaceutical and Gedeon Richter. Under their agreement with AYUMI Pharmaceutical, Mochida will supply the product, while AYUMI will handle its sales in Japan
- Mochida Pharmaceutical and AYUMI Pharmaceutical previously collaborated to commercialize Etanercept BS MA (2018) and Adalimumab BS MA (2021)
Ref: Mochida Pharmaceutical| Image: Mochida Pharmaceutical and AYUMI | Press Release
Related News:- Bio-Thera Expands Collaboration with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) in India
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
